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Abstract
Context: Pharmacological thromboprophylaxis involves a trade-off between a reduction
in venous thromboembolism (VTE) and increased bleeding. No guidance specific for
procedure and patient factors exists in urology.
Objective: To inform estimates of absolute risk of symptomatic VTE and bleeding
requiring reoperation in urological non-cancer surgery.
Evidence acquisition: We searched for contemporary observational studies and esti-
mated the risk of symptomatic VTE or bleeding requiring reoperation in the 4 wk after
urological surgery. We used the GRADE approach to assess the quality of the evidence.
Evidence synthesis: The 37 eligible studies reported on 11 urological non-cancer pro-
cedures. The duration of prophylaxis varied widely both within and between proce-
dures; for example, the median was 12.3 d (interquartile range [IQR] 3.1–55) for open
recipient nephrectomy (kidney transplantation) studies and 1 d (IQR 0–1.3) for percu-
taneous nephrolithotomy, open prolapse surgery, and reconstructive pelvic surgery
studies. Studies of open recipient nephrectomy reported the highest risks of VTE and
bleeding (1.8–7.4% depending on patient characteristics and 2.4% for bleeding). The risk
of VTE was low for 8/11 procedures (0.2–0.7% for patients with low/medium risk; 0.8–
1.4% for high risk) and the risk of bleeding [2_TD$DIFF] was low[13_TD$DIFF] for 6/7 procedures (0.5%; no
bleeding estimates for 4 procedures). The quality of the evidence supporting these
estimates was low or very low.
gh inferences are limited owing to low-quality evidence, our results
ed prophylaxis is warranted for some procedures (eg, kidneyConclusions: Althou
suggest that extend
transplantation procedures in high-risk patients) but not others (transurethral resection
econstructive female pelvic surgery in low-risk patients).of the prostate and r* Corresponding author. Department of Urology, University of Helsinki and Helsinki University
Hospital, Haartmaninkatu 4, Helsinki 00029, Finland. Tel. +358 50 525 0971.
E-mail address: kari.tikkinen@gmail.com (Kari A.O. Tikkinen).
http://dx.doi.org/10.1016/j.eururo.2017.02.025
0302-2838/# 2017 European Association of Urology. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Patient summary: The best evidence suggests that the beneﬁts of blood-thinning drugs to
prevent clots after surgery outweigh the risks of bleeding in some procedures (such as
kidney transplantation procedures in patients at high risk of clots) but not others (such as
prostate surgery in patients at low risk of clots).
# 2017 European Association of Urology. Published by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The volume of urological non-cancer surgery worldwide is
large. In the UK alone, urologists plan more than 200 000
urological operations yearly [1]. Almost all patients under-
going such surgical procedures are at risk of deep vein
thrombosis (DVT) and pulmonary embolism (PE)—together
referred to as venous thromboembolism (VTE)—and major
bleeding.
Whether to use thromboprophylaxis depends on the
trade-off between a reduction in VTE and an increase in
bleeding [2]. The benefits and harms of thromboprophylaxis
critically depend on the risk of VTE and bleeding in those
not receiving thromboprophylaxis, which we refer to as
baseline risk. Prophylaxis is warranted when the baseline
risk of VTE is high and the risk of bleeding is low, but not in
those with low VTE risk and high bleeding risk.
Although the baseline risks of VTE and bleeding in the
absence of prophylaxis vary widely between urological
procedures [3,4], their specific magnitude has not been
established. This uncertainty is, at least in part [4,5],
responsible for substantial practice variation in the use of
thromboprophylaxis in urology, both within and between
countries [6–9]. In an accompanying paper, we provide
baseline risk estimates of VTE and bleeding for surgery in
malignant diseases of the urinary tract and male genital
system [7]. Here, we summarize the evidence regarding
risks of VTE and bleeding in urological non-cancer surgery.
2. Evidence acquisition
Our study protocol, which was prospectively registered
(PROSPERO: CRD42014010342) and previously published
[2], followed PRISMA guidance [10]. Our methods follow
those presented in detail previously [2,7]; here, we
summarize in brief.
2.1. Eligibility
We included observational studies published in English in
which investigators enrolled at least 50 adult patients
undergoing procedures for non-malignant diseases of the
urinary tract or male genital system. Eligible studies
reported absolute estimates of risk for one or more of the
outcomes of interest: fatal PE, symptomatic PE, symptom-
atic DVT, symptomatic VTE, fatal bleeding, and bleeding
requiring reoperation.
2.2. Data sources and searches
For the baseline risk of VTE and bleeding [2], we conducted a
comprehensive systematic search, developed together withexperienced research librarians (N.B. and L.B.), of MEDLINE
from January 1, 2000 to January 1, 2016 (Supplementary
material, pages 58–63). We performed additional searches:
(1) for patient-related risk factors for VTE and bleeding after
surgery; (2) for cohort studies addressing timing of VTE and
bleeding after surgery to inform modeling of outcomes for
studieswith varying follow-up; and (3) for randomized trials
addressing the effects of pharmacological and mechanical
thromboprophylaxis on VTE and bleeding risk after surgery
to calculate baseline risks in patients not receiving
prophylaxis (Supplementary material, pages 64–68).
2.3. Study selection and data abstraction
We used standard methods for systematic reviews for
independent duplicate screening and data extraction
[2,7]. To confirm the accuracy of the data extracted, and
if necessary to clarify missing or unclear information, we
contacted the authors of all the original articles.
2.4. Risk of bias
Through iterative discussion and consensus-building, and
informed by the prior literature [11,12], we developed a novel
instrument to categorize studies as either at lowor high risk of
bias (RoB) in their estimates ofVTEor bleeding risk [2,7]. Items
included the representativeness of the patient population,
thromboprophylaxis documentation, data sources, whether a
majority of patient recruitment years were earlier or later
than 2000, clear specification of the duration of follow-up, and
study type (Supplementary material, page 17).
2.5. Analysis
2.5.1. Outcomes
Outcomes included the absolute risks of symptomatic VTE
and bleeding requiring reoperation (including exploration
and angioembolization) at 4 wk, as well as fatal PE and fatal
bleeding. We analyzed all outcomes separately for each
type of procedure.
2.5.2. Calculating the risk of VTE and bleeding for individual studies
In calculating VTE and bleeding risk, we adjusted analyses
for the extent of thromboprophylaxis use (Supplementary
material, pages 27–28, 30, 34–57), as described in an
accompanying paper. For studies that did not report on use
of thromboprophylaxis, we estimated thromboprophylaxis
use (Supplementary material, page 29).
2.5.3. Choosing the best estimates
Weused themedian value of estimates from eligible studies
to estimate baseline risk of VTE and bleeding requiring
reoperation [2].
Table 1 – Model for risk of venous thromboembolism (VTE)
according to patient risk factors
Risk
Low risk No risk factors 1
Medium risk Any one of the following:
- Age 75 yr
- Body mass index 35 kg/m2
- VTE in ﬁrst-degree relative
(parent, full sibling, or child)
2
High risk Prior VTE
Patients with any combination
of two or more risk factors
4
We developed a very simple model for VTE risk based on studies reporting
the most relevant and compelling evidence [2] identiﬁed in a literature
search addressing VTE risk factors in the context of urology, general
surgery, gynecology, and gastrointestinal surgery. To calculate estimates of
absolute risks for these groups for each procedure, we estimated the
proportion of patients having each of the risk factors using eligible studies.
The calculation principles and model ﬁgures are presented in the
Supplementary material, pages 31–33 and 36–37.
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After assessing the baseline risk of VTE for each procedure,
we estimated risk for groups of patients according to patient
risk factors (Table 1; Supplementary material, pages 31–33,
36–37) [2,7].
2.5.5. Quality of evidence
We used the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) to rate the quality of
evidence (also known as certainty or confidence in
evidence) [7,13,14]. The quality of a body of evidence
drawn from observational studies addressing a question of
prognosis begins as ‘‘high quality’’; in all cases, we rated
down to ‘‘moderate quality’’ because of uncertainties in our
modeling of the risks of VTE and bleeding over time
(Supplementary material, pages 34–35) and in our model of
patient risk strata (Table 1) [2,7]. Whenever identified, we
further rated down for RoB, inconsistency of results,
indirectness of evidence, or imprecision [7].Table 2 – Summary of studies included by procedure a
Procedure Studies found,
n (patients)
P
recruit
Artiﬁcial urinary sphincter 1 (419) 20
Prostatectomy, open simple 1 (232) 20
Sling surgery for male stress urinary incontinence 1 (475) 20
TURP or equivalent b 8 (13 644) 20
Urethroplasty 1 (358) 20
Donor nephrectomy, laparoscopic 11 (1895) 19
Donor nephrectomy, open 3 (502) 19
Recipient nephrectomy, open 5 (1490) 19
Prolapse surgery, open 3 (150) 20
Reconstructive pelvic surgery c 6 (34 692) 19
Percutaneous nephrolithotomy 4 (2497) 19
a If the same patients (same time frame and same institute[s]) were included in m
the median of the means or medians reported in the individual studies. The propo
the individual studies. Reporting prophylaxis: studies reporting a type of prophyl
Supplementary material, pages 14–26.
b Included patients undergoing transurethral resection of the prostate (TURP), la
c Included sling surgery for stress urinary incontinence and vaginal prolapse sur3. Evidence synthesis
3.1. Literature search
For baseline risk estimation, of the 1153 potentially relevant
titles and abstracts identified by the search and 88 articles
provided by the content experts, we judged 311 as
warranting full-text review. Of these, 38 reports addressing
11 urological non-cancer procedures proved eligible (some
articles reported on multiple procedures; further details,
including a flow chart, are provided in the Supplementary
material, pages 69–71): laparoscopic donor nephrectomy
(11 studies), open donor nephrectomy (3 studies), open
recipient nephrectomy (5 studies), percutaneous nephro-
lithotomy (PCNL; 4 studies), transurethral resection of the
prostate (TURP) or equivalent (8 studies), open prolapse
surgery (3 studies), and reconstructive pelvic surgery
(addressing vaginal prolapse and sling surgery; 6 studies)
reporting on both VTE and bleeding, and artificial urinary
sphincter procedure (1 study), open simple prostatectomy
(1 study), sling surgery for male stress urinary incontinence
(1 study), and urethroplasty (1 study) reported only on VTE
(Table 2). On the basis of these studies, we created seven
evidence profiles of the risks of VTE and bleeding and four
evidence profiles without information on bleeding (Sup-
plementary material, pages 3–13). Of the 38 primary study
authors contacted, 22 (58%) confirmed the accuracy of our
data extraction, corrected errors, and/or provided addition-
al information (Supplementary material, page 72).
3.2. Study characteristics and quality of evidence
Table 2 presents the characteristics of the studies for each
procedure (more details are available in the Supplementary
material, pages 14–16). The median of the mean/median
ages varied from 47 yr for donor and recipient nephrecto-
mies to 71 yr for TURP or its equivalent (Table 2). Eligible
studies included two low RoB and 17 high RoB studies foratient
ment years
Median patient
age (yr)
Proportion
of women (%)
Studies reporting
prophylaxis, n (%)
05–2011 NR 0 0 (0)
05–2011 NR 0 0 (0)
05–2011 NR 0 0 (0)
02–2011 71 0 4 (67)
05–2011 NR 0 0 (0)
97–2014 48 58 5 (45)
97–2010 46 50 0 (0)
91–2011 47 39 4 (80)
02–2010 56 100 2 (67)
93–2012 63 100 2 (33)
93–2011 53 52 2 (50)
ore than one study, we included the most comprehensive study. Age is given as
rtion of women is given as the median of the proportions of women reported in
axis, number of patients, and duration of prophylaxis [1_TD$DIFF]. For more details, see the
ser-TURP, and transurethral vaporization in saline.
gery.
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three high RoB studies for PCNL, three low RoB and five
high RoB studies for TURP, two low RoB and one high RoB
study for open prolapse surgery, and two low RoB and four
high RoB studies for reconstructive pelvic surgery
(Supplementary material, pages 18–20). The quality of
evidence was low for risk of VTE and risk of bleeding for
laparoscopic donor nephrectomy; low for risk of VTE and
very low for risk of bleeding for TURP and open prolapse
surgery; and very low for risk of both VTE and bleeding for
all other procedures (Table 3 and Supplementary material,
pages 3–13).Table 3 – The 4-wk postoperative risk of symptomatic nonfatal venous
after urological non-cancer procedures a
Procedure Outcome
Artiﬁcial urinary sphincter VTE
BRR
Prostatectomy, open simple VTE
BRR
Sling surgery for male stress urinary incontinence VTE
BRR
Transurethral resection of the prostate (TURP) or equivalent VTE
BRR
Urethroplasty VTE
BRR
Donor nephrectomy, laparoscopic VTE
BRR
Donor nephrectomy, open VTE
BRR
Recipient nephrectomy, open VTE
BRR
Prolapse surgery (open) VTE
BRR
Reconstructive pelvic surgery b VTE
BRR
Percutaneous nephrolithotomy VTE
BRR
a For more details, see the Supplementary material, pages 3–13.
b Included sling surgery for female stress urinary incontinence and vaginal prola3.3. Thromboprophylaxis use
Most open recipient nephrectomy (80%), open prolapse
surgery (67%), and TURP (67%) studies reported information
on the use of thromboprophylaxis; rates of reporting of
thromboprophylaxis use were lower for other procedures
(median 0%, interquartile range [IQR] 0–40%; Table 2).
Among the studies providing this information, short
duration was reported for PCNL, open prolapse surgery,
and reconstructive pelvic surgery (median 1.0 d, IQR 0–1.3),
longer for laparoscopic donor nephrectomies (median 3.4 d,
IQR 2.0–9.1), and longest for open recipient nephrectomythromboembolism (VTE) and bleeding requiring reoperation (BRR)
Studies,
n (participants)
Estimate by patient
risk strata (%)
Certainty of estimate
1 (419) Low risk:
Medium risk:
High risk:
0.3
0.5
1.0
Very low
Very low
Very low
Not reported
1 (232) Low risk:
Medium risk:
High risk:
2.7
5.4
10.8
Very low
Very low
Very low
Not reported
1 (475) Low risk:
Medium risk:
High risk:
0.4
0.8
1.6
Very low
Very low
Very low
Not reported
4 (13 320) Low risk:
Medium risk:
High risk:
0.2
0.4
0.8
Low
Low
Low
4 (756) 0.2 Very low
1 (358) Low risk:
Medium risk:
High risk:
0.3
0.6
1.1
Very low
Very low
Very low
Not reported
8 (1576) Low risk:
Medium risk:
High risk:
0.4
0.7
1.4
Low
Low
Low
9 (1723) 0.1 Low
1 (383) Low risk:
Medium risk:
High risk:
0.3
0.7
1.3
Very low
Very low
Very low
9 (1723) 0.1 Very low
4 (1350) Low risk:
Medium risk:
High risk:
1.3
2.7
5.3
Very low
Very low
Very low
2 (653) 2.3 Very low
3 (1783) Low risk:
Medium risk:
High risk:
0.2
0.3
0.7
Low
Low
Low
2 (150) 0.4 Very low
4 (44 965) Low risk:
Medium risk:
High risk:
0.1
0.3
0.5
Very low
Very low
Very low
4 (982) 0.3 Very low
2 (441) Low risk:
Medium risk:
High risk:
0.2
0.4
0.7
Very low
Very low
Very low
5 (2780) 0.9 Low
pse.
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21–23).
3.4. Postoperative (4 wk) risk of symptomatic VTE and bleeding
requiring reoperation
Patients undergoing open recipient nephrectomy proved at
high risk of VTE (range 1.3–5.3% across risk groups) and at
appreciable risk of bleeding requiring reoperation (2.3%),
whereas patients undergoing donor nephrectomy (both
laparoscopic and open) were at lower risk of both VTE
(range 0.4–1.4% for laparoscopic and 0.3–1.3% for open
across risk groups) and bleeding requiring reoperation (0.1%
for both; Table 3 and Supplementary material, pages 24–
26). The risks of VTE and bleeding requiring reoperation
were <1.0% for all risk groups after TURP, open prolapse
surgery, reconstructive pelvic surgery, and PCNL. For a
number of procedures, studies reported only VTE risk. For
these, the incidence was lowest for artificial urinary
sphincter (0.3–1.0%), slightly higher for urethroplasty
(0.3–1.10%), somewhat higher for sling surgery for male
stress incontinence (0.4–1.6%), and much higher for open
simple prostatectomy (2.7–10.8%), with the quality of
evidence very low in all cases.
3.5. Discussion
This systematic review provides the first summary of best
estimates of the baseline risk of symptomatic VTE and
serious bleeding for major non-cancer surgeries in urology.
Among urological non-cancer procedures for which we
were able to estimate both VTE and bleeding risks, the
highest baseline risk of VTE at 4 wk was observed for open
recipient nephrectomy (1.3–5.3%), for which the risk varied
with patient factors (age, BMI, and personal or family
history of VTE; Table 3). Patients undergoing donor
nephrectomy were at lower risk of VTE than those
undergoing recipient nephrectomy (range 0.4–1.4% for
laparoscopic and 0.3–1.3% for open surgery across risk
groups). The risk of VTE was <1.0% for all risk groups after
TURP, open prolapse surgery, reconstructive pelvic surgery,
and PCNL (Table 3).
Among urological non-cancer procedures, studies on
open recipient nephrectomy reported the highest baseline
risk of bleeding requiring reoperation at 4 wk (2.4%),
followed by studies on PCNL (0.9%). The risk of bleeding
requiring reoperation was 0.5% for all other non-cancer
procedures. Certainty for both VTE and bleeding estimates
was either low or very low (Table 3).
3.6. Strengths and limitations
The strengths of our study include a contemporary and
procedure-specific search; rigorous adherence to method-
ological standards, including duplicate assessment of
eligibility and data abstraction, and checking of abstracted
data by a methodologist clinician; systematic appraisal of
RoB; and assessment of the quality of evidence using the
GRADE system [13,14]. Successful communication withmany of the authors of the studies included provided far
more complete data than the original publications alone. To
optimize the applicability to current practice, we used only
studies in which all patients underwent surgery in 1990 or
thereafter. We developed novel methods for constructing
models for estimation that considered the length of follow-
up, the use of thromboprophylaxis, and patient risk factors
[2,7].
The limitations of our review are largely those of the
original studies. Many studies did not provide information
regarding the use of thromboprophylaxis or the precise
length of follow-up [15–17]. Studies were generally at high
risk of bias; the modeling approaches—including assump-
tions for thromboprophylaxis use—we needed to use are
associated with unavoidable uncertainty, and estimates
were often associated with substantial imprecision [7]. As a
result, we categorized the evidence as low or very low in
quality, reducing the strength of inferences that can be
drawn from the evidence.
3.7. Clinical implications
These summaries shouldhave important implications for the
practice of urological surgery worldwide. Both anecdotally
and in the formal comparisons undertaken, post-discharge
thromboprophylaxis practice varies widely both within and
between countries. Our results were consistent with this
evidence:we found that therewas very large variation in the
use of thromboprophylaxis across studies [6–8].
When estimates clearly suggest that the benefits of VTE
prevention outweigh over risks of bleeding (ie, for all types
of kidney transplantation procedure in high-risk patients),
or conversely when estimates clearly show that bleeding
risks outweigh any benefit from thromboprophylaxis (ie, in
TURP, PCNL and reconstructive female pelvic surgery in
low-risk patients) such variation is problematic. When the
trade-off is closer ([14_TD$DIFF]for [15_TD$DIFF]instance, open prolapse surgery in
high-risk patients), evaluation of the benefits versus risks of
thromboprophylaxis will differ across surgeons and
patients, and one would expect practice to vary.
Our work highlights that in non-cancer urology the
evidence is of low or very low quality, even for procedures
with high volumes and non-negligible risks, including
kidney transplantation and TURP. Therefore, the generation
of higher-quality evidence should constitute a research
priority. This research should adhere to methodological
standards that have seldom been observed thus far,
including comprehensive characterization of patient popu-
lations and follow-up times, documentation of prophylaxis
use, and reproducible measurements of DVT, PE, and
bleeding. Studies on the importance that patients place
on avoiding VTE versus avoiding bleeding would further
enhance optimal decision-making regarding thrombopro-
phylaxis for urological procedures.
4. Conclusions
The current evidence suggests a net benefit of VTE
prophylaxis for some procedures (kidney transplantation
E U RO P E AN URO L OGY 7 3 ( 2 0 1 8 ) 2 3 6 – 2 4 1 241procedures in high-risk patients) but that bleeding risks
outweigh the benefits of thromboprophylaxis (net harm)
for others (TURP and reconstructive female pelvic surgery in
low-risk patients). The evidence regarding the baseline risk
of VTE and bleeding in non-cancer urology is of low or very
low quality; generating higher-quality evidence should
constitute a research priority.
Author contributions: Kari A.O. Tikkinen had full access to all the data in
the study and takes responsibility for the integrity of the data and the
accuracy of the data analysis.
Study concept and design: Tikkinen, Guyatt.
Acquisition of data: Tikkinen, Craigie, Agarwal, Siemieniuk, Cartwright,
Violette, Novara, Naspro, Agbassi, Ali, Imam, Ismaila, Kam.
Analysis and interpretation of data: Tikkinen, Craigie, Siemieniuk,
Cartwright, Violette, Novara, Naspro, Gould, Sandset, Guyatt.
Drafting of the manuscript: Tikkinen, Craigie, Agarwal.
Critical revision of the manuscript for important intellectual content:
Tikkinen, Craigie, Agarwal, Siemieniuk, Cartwright, Violette, Novara,
Naspro, Agbassi, Ali, Imam, Ismaila, Kam, Gould, Sandset, Guyatt.
Statistical analysis: Tikkinen, Craigie, Guyatt.
Obtaining funding: Tikkinen.
Administrative, technical, or material support: None.
Supervision: Tikkinen, [16_TD$DIFF]Guyatt.
[3_TD$DIFF]Other: None.
Financial disclosures: Kari A.O. Tikkinen certiﬁes that all conﬂicts of
interest, including speciﬁc ﬁnancial interests and relationships and
afﬁliations relevant to the subject matter or materials discussed in the
manuscript (eg, employment/afﬁliation, grants or funding, consultan-
cies, honoraria, stock ownership or options, expert testimony, royalties,
or patents ﬁled, received, or pending), are the following: Philippe D.
Violette has received honoraria from Astellas, Janssen [17_TD$DIFF], Pﬁzer, and [18_TD$DIFF]Sanoﬁ.
Giacomo Novara has been an advisory board member and speaker for
Astellas, GlaxoSmithKline, Lilly, Menarini, Nycomed, Pﬁzer, Pierre Fabre,
and Recordati. Richard Naspro has been an advisory board member for
Ipsen, and a speaker for Ipsen, Lumenis, and Storz. The remaining authors
have no ﬁnancial conﬂicts of interest to disclose.
Funding/Support and role of the sponsor: The Risk of Thrombosis and
Bleeding in Urological Surgery (ROTBUS) project was conducted by the
Clinical Urology and Epidemiology (CLUE) Working Group and
supported by the Academy of Finland (#276046), Competitive Research
Funding from the Helsinki and Uusimaa Hospital District, the European
Association of Urology Guidelines Ofﬁce, the Finnish Cultural Founda-
tion, the Finnish Medical Foundation, the Jane and Aatos Erkko
Foundation, and the Sigrid Juse´lius Foundation. Rufus Cartwright was
also supported by a Research Training Fellowship from the UK Medical
Research Council. Philippe D. Violette was also supported by the
Canadian Urological Association Scholarship Foundation. The funders
had no role in the study design and conduct, data collection, analysis, and
interpretation, or manuscript preparation, review, and approval.
Acknowledgments: The authors would like to thank Alpesh N. Amin,
Valerie Beral, John Eikelboom, Yngve Falck-Ytter, Jack Hirsch, Bo¨rje
Ljungberg, and Sian Sweetland for insightful comments regarding data
analysis; information scientists Laura Banﬁeld and Neera Bhatnagar for
advice regarding literature search strategies; and researchers for
checking extracted data for accuracy and/or providing additional
information regarding the original studies (Supplementary material,
page 72). We would also like to thank ROTBUSWorking Group members
for their contributions to the planning and conduct of this project.
ROTBUS Working Group members are Arnav Agarwal, Chika Agbassi,Bassel Ali, Rufus Cartwright, Samantha Craigie, Leyla Eryuzlu, Johanna
Geraci, Michael K. Gould, Gordon H. Guyatt, Jari Haukka, Maha Imam,
Noﬁsat Ismaila, Denise Kam, Richard Naspro, Giacomo Novara, Per
Morten Sandset, Reed Siemieniuk, Kari A.O. Tikkinen, Philippe D.
Violette, Judi Winkup, and Daniel Yoo.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/j.
eururo.2015.10.045.
References
[1] National Health Service. What HES data are available?. National
Health Service Digital; 2016,. www.hscic.gov.uk/hesdata
[2] Tikkinen KA, Agarwal A, Craigie S, et al. Systematic reviews of
observational studies of risk of thrombosis and bleeding in urologi-
cal surgery (ROTBUS): introduction and methodology. Syst Rev
2014;3:150.
[3] National Institute for Health and Care Excellence. NICE clinical
guideline (CG92). Venous thromboembolism: reducing the risk
for patients in hospital. www.nice.org.uk/guidance/cg92.
[4] Forrest JB, Clemens JQ, Finamore P, et al. AUA Best Practice State-
ment for the prevention of deep vein thrombosis in patients un-
dergoing urologic surgery. J Urol 2009;181:1170–7.
[5] Violette PD, Cartwright R, Briel M, Tikkinen KA, Guyatt GH. Guide-
line of guidelines: thromboprophylaxis for urologic surgery. BJU Int
2016;118:351–8.
[6] Tyson MD, Castle EP, Humphreys MR, Andrews PE. Venous throm-
boembolism after urological surgery. J Urol 2014;192:793–7.
[7] Tikkinen KA, Craigie S, Agarwal A, et al. Procedure-speciﬁc risks of
thrombosis and bleeding in urological cancer surgery: systematic
reviews and meta-analyses. Eur Urol 2018;73:242–51.
[8] Soloway MS. Thromboembolism prophylaxis and total prostatec-
tomy: is pharmacologic therapy required? Eur Urol 2008;53:21–3.
[9] Eberli D. Optimal thromboprophylaxis remains a challenge. BJU Int
2016;118:342.
[10] Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred
reporting items for systematic reviews and meta-analyses: the
PRISMA statement. BMJ 2009;339:b2535.
[11] Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. Rating the
quality of evidence-study limitations (risk of bias). J Clin Epidemiol
2011;64:407–15.
[12] Kim SY, Park JE, Lee YJ, et al. Testing a tool for assessing the risk of
bias for nonrandomized studies showed moderate reliability and
promising validity. J Clin Epidemiol 2013;66:408–14.
[13] Guyatt GH, Oxman AD, Kunz R, et al. What is ‘quality of evidence’
and why is it important to clinicians? BMJ 2008;336:995–8.
[14] Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consen-
sus on rating quality of evidence and strength of recommendations.
BMJ 2008;336:924–6.
[15] Mueller MG, Pilecki MA, Catanzarite T, et al. Venous thromboem-
bolism in reconstructive pelvic surgery. Am J Obstet Gynecol
2014;211, 552.e1–e6.
[16] Moscarelli L, Zanazzi M, Bertoni E, et al. Renin angiotensin system
blockade and activated vitamin D as a means of preventing deep
vein thrombosis in renal transplant recipients. Clin Nephrol
2011;75:440–50.
[17] Srivastava A, Singh KJ, Suri A, et al. Vascular complications after
percutaneous nephrolithotomy: are there any predictive factors?
Urology 2005;66:38–40.
